[{"id":"a6865147-d492-4b7c-ab7e-c32c506cfa4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02500550","created_at":"2022-01-21T22:01:20.459Z","updated_at":"2024-07-02T16:36:30.087Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor","source_id_and_acronym":"NCT02500550","lead_sponsor":"Kiadis Pharma","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rhitol (allodepleted T-cell immunotherapeutics) • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/09/2015","start_date":" 10/09/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 12/17/2018","study_completion_date":" 12/17/2018","last_update_posted":"2021-05-18"}]